Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2024-05-30 DOI:10.1016/j.ccell.2024.05.006

Yihong Li, Min Huang, Minger Wang, Yi Wang, Peng Deng, Chunni Li, Jingying Huang, Hui Chen, Zhihao Wei, Qian Ouyang, Jinghua Zhao, Yiwen Lu, Shicheng Su

{"title":"Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite","authors":"Yihong Li, Min Huang, Minger Wang, Yi Wang, Peng Deng, Chunni Li, Jingying Huang, Hui Chen, Zhihao Wei, Qian Ouyang, Jinghua Zhao, Yiwen Lu, Shicheng Su","doi":"10.1016/j.ccell.2024.05.006","DOIUrl":null,"url":null,"abstract":"Tumors employ various strategies to evade immune surveillance. Central nervous system (CNS) has multiple features to restrain immune response. Whether tumors and CNS share similar programs of immunosuppression is elusive. Here, we analyze multi-omics data of tumors from HER2+ breast cancer patients receiving trastuzumab and anti-PD-L1 antibody and find that CNS-enriched N-acetyltransferase 8-like (NAT8L) and its metabolite N-acetylaspartate (NAA) are overexpressed in resistant tumors. In CNS, NAA is released during brain inflammation. NAT8L attenuates brain inflammation and impairs anti-tumor immunity by inhibiting cytotoxicity of natural killer (NK) cells and CD8+ T cells via NAA. NAA disrupts the formation of immunological synapse by promoting PCAF-induced acetylation of lamin A-K542, which inhibits the integration between lamin A and SUN2 and impairs polarization of lytic granules. We uncover that tumor cells mimic the anti-inflammatory mechanism of CNS to evade anti-tumor immunity and NAT8L is a potential target to enhance efficacy of anti-cancer agents.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":null,"pages":null},"PeriodicalIF":48.8000,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ccell.2024.05.006","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Tumors employ various strategies to evade immune surveillance. Central nervous system (CNS) has multiple features to restrain immune response. Whether tumors and CNS share similar programs of immunosuppression is elusive. Here, we analyze multi-omics data of tumors from HER2⁺ breast cancer patients receiving trastuzumab and anti-PD-L1 antibody and find that CNS-enriched N-acetyltransferase 8-like (NAT8L) and its metabolite N-acetylaspartate (NAA) are overexpressed in resistant tumors. In CNS, NAA is released during brain inflammation. NAT8L attenuates brain inflammation and impairs anti-tumor immunity by inhibiting cytotoxicity of natural killer (NK) cells and CD8⁺ T cells via NAA. NAA disrupts the formation of immunological synapse by promoting PCAF-induced acetylation of lamin A-K542, which inhibits the integration between lamin A and SUN2 and impairs polarization of lytic granules. We uncover that tumor cells mimic the anti-inflammatory mechanism of CNS to evade anti-tumor immunity and NAT8L is a potential target to enhance efficacy of anti-cancer agents.

Abstract Image

查看原文本刊更多论文

肿瘤细胞通过富含中枢神经系统的代谢物损害免疫突触的形成

肿瘤采用各种策略逃避免疫监视。中枢神经系统（CNS）具有抑制免疫反应的多种特征。肿瘤和中枢神经系统是否共享类似的免疫抑制程序尚不明确。在这里，我们分析了接受曲妥珠单抗和抗PD-L1抗体治疗的HER2+乳腺癌患者肿瘤的多组学数据，发现中枢神经系统富含的N-乙酰转移酶8样（NAT8L）及其代谢产物N-乙酰天冬氨酸（NAA）在耐药肿瘤中过度表达。在中枢神经系统中，NAA 在脑部炎症期间释放。NAT8L 通过 NAA 抑制自然杀伤（NK）细胞和 CD8+ T 细胞的细胞毒性，从而减轻脑部炎症并损害抗肿瘤免疫。NAA通过促进PCAF诱导的片层蛋白A-K542乙酰化破坏免疫突触的形成，从而抑制片层蛋白A和SUN2之间的整合，并损害裂解颗粒的极化。我们发现肿瘤细胞模仿中枢神经系统的抗炎机制来逃避抗肿瘤免疫，而NAT8L是提高抗癌药物疗效的潜在靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.